Recombinant growth-hormone protein medicine · Fact sheet
Somatropin
Also known as Recombinant human growth hormone · rhGH · Genotropin
Somatropin is recombinant human growth hormone with product-specific approved deficiency and growth indications. Studies in healthy older people found body-composition changes without dependable functional benefit and with frequent adverse effects.
What is Somatropin?
Somatropin replaces growth hormone; it is different from GHRH analogs or ghrelin-receptor secretagogues that stimulate release.
Brands and long-acting modified growth-hormone products have different labels and schedules.
Benefits & claims
Interest includes deficiency replacement and body composition. More lean mass does not necessarily mean greater strength, endurance or longer life.
What the evidence supports
- Genotropin adult deficiency trials support replacement-related outcomes in the selected population.
- A healthy-older-men trial changed body composition without improving strength or endurance.
- The aging trial findings do not establish rejuvenation or justify general performance claims.
Research areas
- Adult growth-hormone deficiency
- Product-specific pediatric growth disorders
- Experimental healthy-aging use
Dosage & frequency
Product-specific label informationThis is one Genotropin adult GH-deficiency dosing approach; it is not a pediatric, bodybuilding or anti-aging schedule.
Genotropin, adult non-weight-based label approach
Adults meeting the label criteria for childhood- or adult-onset growth-hormone deficiency
- Amount
- Approximate starting amount 0.2 mg/day; labeled starting range 0.15–0.30 mg/day
- Frequency
- Daily; gradual adjustment every one to two months according to response and IGF-1
- Route studied or labeled
- Subcutaneous prescription treatment
Label adjustment increments are approximately 0.1–0.2 mg/day, with reductions for adverse effects or excessive IGF-1. Age, sex, estrogen exposure and obesity affect requirements. The alternative weight-based and pediatric schedules are omitted; no fixed duration is specified.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Somatropin replaces growth hormone; it is different from GHRH analogs or ghrelin-receptor secretagogues that stimulate release.
Formulation differences
- Brands and long-acting modified growth-hormone products have different labels and schedules.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term benefit-risk outside approved deficiency settings
- Whether lean-mass changes improve meaningful function
- Comparability of products and long-acting analogs
Side effects & risks
- Glucose intolerance, diabetes, fluid retention and musculoskeletal symptoms are material risks.
- The label includes contraindications involving acute critical illness, active malignancy and certain severe respiratory-risk situations in children with Prader-Willi syndrome.
- Intracranial hypertension and other endocrine or orthopedic complications require clinical monitoring.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesApproved replacement is supported by product-specific evidence. Healthy-older-adult trials found limited functional changes despite changes in lean and fat mass, with frequent adverse effects.
Studies
52 healthy older men; body composition improved without functional benefit.
Healthy older-adult randomized trial; frequent adverse effects including glucose intolerance.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Genotropin is approved for defined adult GH deficiency and specified pediatric growth disorders. Other brands have their own indications; approval does not extend to general anti-aging or bodybuilding.
Approved uses
- Genotropin for label-defined adult GH deficiency and specified pediatric growth disorders, including pediatric GHD, Prader-Willi syndrome, Turner syndrome, small-for-gestational-age growth failure and idiopathic short stature.
FDA approved for a specific product and use
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term benefit-risk outside approved deficiency settings
- Whether lean-mass changes improve meaningful function
- Comparability of products and long-acting analogs
Summary
The aging trial findings do not establish rejuvenation or justify general performance claims.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- nihGenotropin prescribing information
Current product-specific adult and pediatric indications, individualized dosing and contraindications.
- pubmedGrowth hormone replacement in healthy older men improves body composition but not functional ability.
52 healthy older men; body composition improved without functional benefit.
- pubmedGrowth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.
Healthy older-adult randomized trial; frequent adverse effects including glucose intolerance.